Clinical Trial Update: Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating trastuzumab and pyrotinib combined with dalpiciclib and endocrine therapy for HR+/HER2+ advanced breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasm

Drugs mentioned

• Dalpiciclib (dalpiciclib)
• Endocrine therapy
• Pyrotinib (pyrotinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Breast Neoplasm Female | Phase 2 | Status: UNKNOWN